Related Experiment Videos
Protein kinase C mu is down-regulated in androgen-independent prostate cancer
Meena Jaggi1, Prema S Rao, David J Smith
1Division of Urology, Department of Surgery, University of Nebraska Medical Center, 982360 Nebraska Medical Center, Omaha, NE 68198-2360, USA.
Abstract:
Progression to androgen independence (AI) is the main cause of death in prostate cancer. Our prior differential gene expression studies by microarray analysis in progressive prostate cancer cell line model identified dysregulation of protein kinase C mu (PKCmu) expression in prostate cancer. In this study, quantitative ribonuclease protection assay and immunoblot analysis demonstrate down regulation of PKCmu at transcription and translational level, respectively, in AI C4-2 cells compared to its parental androgen dependent (AD) LNCaP prostate cancer cells. Significantly lower PKCmu kinase activity was confirmed in C4-2 cells by in vitro kinase assay. Immunohistochemical studies of prostate cancer tissue from patient progressing to AI prostate cancer demonstrated that PKCmu expression is decreased in 100% of AI human prostate cancers. The consistent down regulation of PKCmu in cell line models and human prostate cancer tissues suggests a possible functionally significant role for PKCmu in progression to AI in prostate cancer.
Insights
Protein kinase C mu (PKCmu) is downregulated in prostate cancer progression to androgen independence (AI). This decrease in PKCmu expression and activity suggests a significant role in AI progression, impacting survival rates.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer progression to androgen independence (AI) is a primary cause of mortality.
- Previous studies indicated dysregulation of protein kinase C mu (PKCmu) in prostate cancer progression.
Purpose of the Study:
- To investigate the role of PKCmu in the progression of prostate cancer to androgen independence.
- To quantify PKCmu expression and activity in androgen-dependent and independent prostate cancer models.
Main Methods:
- Quantitative ribonuclease protection assay to assess PKCmu transcription.
- Immunoblot analysis to evaluate PKCmu translation.
- In vitro kinase assay to measure PKCmu activity.
- Immunohistochemical analysis of patient prostate cancer tissues.
Main Results:
- PKCmu expression was downregulated at both transcriptional and translational levels in AI C4-2 cells compared to AD LNCaP cells.
- PKCmu kinase activity was significantly lower in AI C4-2 cells.
- Immunohistochemical analysis revealed decreased PKCmu expression in 100% of human AI prostate cancers.
Conclusions:
- Consistent downregulation of PKCmu in cell line models and human tissues suggests a significant functional role in prostate cancer progression to AI.
- Targeting PKCmu may offer a therapeutic strategy for advanced prostate cancer.